COMPOUNDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF COVID-19

A research group from CIBER, FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD (FPS) and SERVICIO ANDALUZ DE SALUD (SAS) has identified suitable compounds for the prevention and/or treatment of COVID-19.

The Need
COVID-19 disease is a major worldwide health problem because of its associated morbidity and mortality.

Despite the extensive vaccination campaigns in many countries, there’s still an urgent unmet medical need of discovering drugs that could be used for the prevention and as an efficient therapies against the disease.

The Solution
Identification of specific compounds of a pharmaceutical composition for the use in prevention and/or treatment of COVID-19 (particularly a Coronavirus infection, more particularly a SARS-CoV-2 infection), based on data collection from the electronic health record (EHR) of Andalusian patients in the Health Population Base (BPS).

Innovative Aspects
The main innovate aspect consists on the use of data from a central registry of EHR (the Andalusian Population Health Database, BSS) for the assessment of the effect of prior consumption of drugs for other indication previous to the hospitalization with respect to patient survival to COVID-19.

The present invention also refers to a method of preventing and/or treating COVID-19 which comprises the administration of a therapeutically effective amount or dose of any of the compounds identified, or a combination thereof, comprising these compounds in combination with pharmaceutically acceptable excipients or carriers.

Stage of Development:
Compounds selected from data collected from a large retrospective cohort of 15,968 hospitalized patients

Figure 1. 21 drugs showed significant increase in lymphocyte counts, marker of COVID severity, after correction for the possible confusion covariables and for multiple testing.

Figure 2. Survival estimations showed that a total of 21 drugs have a significant effect on patient survival.

Intellectual Property:
- Priority European patent application (October 10, 2021)
- PCT application (July 15, 2022)

Aims
Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

Contact details
Consorcio Centro de Investigación Biomédica en Red (CIBER)
otc@ciberisciii.es
https://www.ciberisciii.es/en